News | February 28, 2022
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Subscribe To Our Newsletter & Stay Updated
